Trial Profile
VEGF, VEGFR1 and VEGFR2 expression in serous epithelial ovarian carcinoma, and its association to the efficacy of bevacizumab combined with paclitaxel and carboplatin as first line treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Carcinoma; Ovarian cancer
- Focus Therapeutic Use
- 18 Sep 2022 Status changed from recruiting to completed.
- 02 Aug 2014 New trial record